Overview

To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent

Status:
Terminated

Trial end date:
2005-04-01

Target enrollment:

Participant gender:

Summary

To determine the Objective Response Rate of 4 cycles of docetaxel + anthracycline (epirubicin or doxorubicine) followed by 4 cycles of docetaxel single agent. To determine the Time to Tumor Progression (TTP), the Response Duration, the Overall Survival. To confirm the safety profile

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Docetaxel
Doxorubicin
Epirubicin